Trials / Sponsors / Steven E. Coutre
Steven E. Coutre
Academic / Other · 7 registered clinical trials.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Completed | Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL Recurrent Chronic Lymphocytic Leukemia, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia | Phase 2 | 2017-09-26 |
| Terminated | Ibrutinib, Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Recurrent Adult Acute Myeloid Leukemia | Phase 1 | 2016-11-01 |
| Terminated | Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a) | Phase 2 | 2014-03-01 |
| Completed | Temozolomide Plus Vorinostat in Relapse/Refractory Acute Myeloid Leukemia (AML) Acute Myeloid Leukemia With 11q23-abnormality in Relapse | Phase 2 | 2013-05-01 |
| Completed | Monoclonal Antibody (mAb) 216 With Chemotherapy in Adult Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia, Lymphocytic, Leukemia, Acute Lymphocytic Leukemia | Phase 1 | 2006-05-01 |
| Completed | Phase 2 Fludarabine, Cytoxan and FCCAM <Alemtuzumab> in Untreated B-Cell Chronic Lymphocytic Leukemia Leukemia, B-cell Leukemia, Chronic Leukemia | Phase 2 | 2004-07-01 |
| Terminated | Phase II Gleevec Idiopathic Hypereosinophilic Syndrome Eosinophilia, Hypereosinophilic Syndrome | Phase 2 | 2003-06-12 |